Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes
We examined whether baseline plasma levels of markers of inflammation and endothelial dysfunction are associated with the incidence of diabetic retinopathy (DR) in African Americans with type 1 insulin-dependent diabetes mellitus (T1DM). At baseline and follow-up examinations, detailed ocular examin...
Saved in:
Published in | Investigative ophthalmology & visual science Vol. 54; no. 8; pp. 5471 - 5480 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
The Association for Research in Vision and Ophthalmology
13.08.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | We examined whether baseline plasma levels of markers of inflammation and endothelial dysfunction are associated with the incidence of diabetic retinopathy (DR) in African Americans with type 1 insulin-dependent diabetes mellitus (T1DM).
At baseline and follow-up examinations, detailed ocular examination, structured clinical interview, venous blood specimens, and masked grading of seven standard field retinal photographs were obtained. Baseline plasma levels of 28 inflammatory biomarkers, measured using multiplex bead analysis system, were measured in the participants.
After adjusting for age, glycemic control, and other potential confounders, baseline plasma levels of E-selectin were associated significantly with progression of DR, E-selectin and tumor necrosis factor-α (TNF-α) levels with incidence of proliferative DR (PDR), and soluble intercellular adhesion molecule-1 (sICAM-1) and TNF-α levels with incidence of macular edema (ME).
In African Americans with T1DM, inflammation and endothelial dysfunction precede the development of DR, thus supporting the notion that inflammation may influence progression/incidence of disease. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1552-5783 0146-0404 1552-5783 |
DOI: | 10.1167/iovs.13-12212 |